LUMIGAN® (bimatoprost ophthalmic solution)
LUMIGAN® 0.03% UD is indicated for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers):1
LUMIGAN® (bimatoprost ophthalmic solution 0.01%)
LUMIGAN® (bimatoprost ophthalmic solution 0.03% MD)
What is LUMIGAN® 0.03% UD and how does it work?
LUMIGAN® 0.03% UD belongs to a class drugs known as prostaglandin analogs1
Prostaglandin analogs like LUMIGAN® 0.03% UD work by increasing aqueous humor outflow through the trabecular meshwork and enhancing uveoscleral outflow.1
LUMIGAN® 0.03% UD offers a dual mechanism of action1
The dual mechanism of action stimulates aqueous humour outflow via the trabecular meshwork and uveoscleral pathways, which work together to help lower IOP.1
1 – Increases trabecular meshwork outflow1
2 – Increases uveoscleral outflow1
Image adapted from American Academy of Ophthalmology. 2017.2
Copy from LUMIGAN® 0.03% UD Summary of Product Characteristics. 2022.1
Administration and dosing of LUMIGAN® 0.03% UD
One drop should be administered into the affected eye(s) once daily, in the evening.1
The dose should not exceed once daily, as more frequent administration may lessen the intraocular pressure lowering effect.1
LUMIGAN® 0.03% UD is available in convenient single unit-dose containers. For single use only, one container is sufficient to treat both eyes. Any unused solution should be discarded immediately after use.1
LUMIGAN® 0.03% UD may not be suitable for some of your patients
LUMIGAN® 0.03% UD is contraindicated in:1
Patients with hypersensitivity to the active substance (bimatoprost) or any of the excipients (sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate, hydrochloric acid or sodium hydroxide [to adjust pH], or purified water).
Please refer to LUMIGAN® 0.03% UD Summary of Product Characteristics for full safety information and precautions for use.
LUMIGAN® 0.3 mg/mL unit dose is indicated for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).1
In a 3-month clinical study, approximately 29% of patients treated with LUMIGAN® 0.3 mg/mL unit dose experienced adverse reactions. The most frequently reported adverse reactions were conjuctival hyperemia (mostly trace to mild and of a non-inflammatory nature) occurring in 24% of patients, and eye pruritis occurring in 4% of patients. Approximately 0.7% of patients in the LUMIGAN® 0.3 mg/mL single-dose group discontinued due to any adverse event in the 3 month study.1
Please refer to LUMIGAN® 0.03% UD Summary of Product Characteristics for further information on adverse events.